Биология ва тиббиёт муаммолари 2023 №5.1 (149)

Maqola mavzusi

ИНКРУСТИРУЮЩИЙ ЦИСТИТ (120-131)

Mualliflar

Мухтаров Шухрат Турсунович, Акилов Фархад Атауллаевич, Егоров Александр Борисович, Насиров Фуркат Раупович, Джамилов Джалол Джамалович, Дадаханов Нодир Эркинович

Muassasa

Республиканский специализированный научно-практический медицинский центр урологии, Республика Узбекистан, г. Ташкент

Annotatsiya

Инкрустирующий цистит – довольно редкое и не до конца изученное заболевание, характеризующееся хроническим воспалительным процессом, часто рецидивирующим течением, которое проявляется инкрустацией слизистой мочевого пузыря, то есть отложением фосфата аммония и магния, а также струвита на поверхности слизистой мочевого пузыря, которая со временем становится интимно спаянной с подслизистой, а иногда и с мышечной стенкой мочевого пузыря. Частой причиной заболевания является уреазопродуцирующие бактерии в моче, в основном Corynebacterium urealyticum. В результате инфекционно-воспалительного процесса повышается pH мочи, что приводит к формированию инкрустации и её отложению на уротелии. Сложность ранней диагностики данного заболевания ведет к усугублению инкрустирующего цистита и развитию осложнений. Ключевым фактором при лечении инкрустирующего цистита является комбинированная рациональная терапия с удалением инкрустации, подкислением мочи и продолжительным приемом антибиотиков.

Kalit so'zlar

инкрустирующий цистит, уреазопродуцирующая бактерия, Corynebacterium urealyticum, инкрустированная уропатия.

Adabiyotlar

1. François J. La cystite incrustée. J Urol Méd Chir. (1914) 5:35–52. 2. Hager BH, Magath TB. The etiology of incrusted cystitis with alkaline urine. J Am Med Assoc. (1925) 85:1352–5. 10.1001/jama.1925.02670180008002 3. Soriano F, Aguado JM, Ponte C, Fernández-Roblas R, Rodríguez-Tudela JL. Urinary tract infection caused by Corynebacterium group D2: report of 82 cases and review. Rev Infect Dis. (1990) 12:1019–34. 10.1093/clinids/12.6.1019 4. Nebreda-Mayoral T, Muñoz-Bellido JL, Garcia-Rodríguez JA. Incidence and characteristics of urinary tract infections caused by Corynebacterium urealyticum (Corynebacterium group D2). Eur J Clin Microbiol Infect Dis. (1994) 13:600–4. 10.1007/BF01971313 5. Sánchez-Martín FM, López-Martínez JM, Kanashiro-Azabache A, Moncada E, Angerri-Feu O, Millán-Rodríguez F, et al.. Corynebacterium urealyticum: increased incidence of infection and encrusted uropathy. Actas Urol Esp. (2016) 40:102–7. 10.1016/j.acuroe.2016.01.007 6. Soriano F, Ponte C, Santamaría M, Aguado JM, Wilhelmi I, Vela R, et al.. Corynebacterium group D2 as a cause of alkaline-encrusted cystitis: report of four cases and characterization of the organisms. J Clin Microbiol. (1985) 21:788–92. 10.1128/JCM.21.5.788-792.1985 7. Curry CR, Saluja K, Das S, Thakral B, Dangle P, Keeler TC, et al.. Encrusted cystitis secondary to Corynebacterium glucuronolyticum in a 57-year-old man without predisposing factors. Lab Med. (2015) 46:136–9. 10.1309/LMXQP557EINXBXIF 8. Гаджиев Н.К., Маликиев И.Е., Обидняков В.М., Горелов Д.С., Шкарупа Д.Д., Гаджиева З.К., Мартов А.Г., Петров С.Б. Проблемы клинической диагностики и лечения инкрустирующего цистита, Журнал «Урология», Москва 2022, 142-146 с. ISSN: 1728-2985eISSN: 2414-9020 9. Aguado JM, Morales JM, Salto E, Lumbreras C, Lizasoain M, Diaz-Gonzalez R, et al.. Encrusted pyelitis and cystitis by Corynebacterium urealyticum (CDC group D2): a new and threatening complication following renal transplant. Transplantation. (1993) 56:617–22. 10.1097/00007890-199309000-00023 10. Benoit G, Blanchet P, Eschwege P, Alexandre L, Bensadoun H, Charpentier B. Insertion of a double pigtail ureteral stent for the prevention of urological complications in renal transplantation: a prospective randomized study. J Urol. (1996) 156:881–4. 10.1016/S0022-5347(01)65647-7 11. Benoit G, Eschwege P, Paradis V, Droupy S, Nordmann P, Charpentier B. Successful treatment of encrusted pyelitis in a renal transplant with local acidification and surgical ileocaliceal anastomosis. J Urol. (1999) 162:1369–70. 10.1016/S0022-5347(05)68292-4 12. Coyle MB, Lipsky BA. Coryneform bacteria in infectious diseases: clinical and laboratory aspects. Clin Microbiol Rev. (1990) 3:227–46. 10.1128/CMR.3.3.227 13. Jameson RM. The treatment of phosphatic en-crusted cystitis (alkaline cystitis) with nalidixic acid. Br J Urol. (1966) 38:89–92. 10.1111/j.1464-410X.1966.tb09682.x 14. Semaan A, Tayeh GA, Chebel JA, Hallit R, Matta M, Hajj P. Arcanobacterium pyogenes and encrusted pyelitis. Future Sci OA. (2019) 6:FSO430. 10.2144/fsoa-2019-0021 15. Soriano F, Rodriguez-Tudela JL, Fernández-Roblas R, Fernández-Roblas R, Aguado JM, Santamaría M. Skin colonization by Corynebacterium groups D2 and JK in hospitalized patients. J Clin Microbiol. (1988) 26:1878–80. 10.1128/JCM.26.9.1878-1880.1988 16. De Briel D, Langs JC, Rougeron G, Chabot P, Le Faou A. Multiresistant corynebacteria in bacteriuria: a comparative study of the role of Corynebacterium group D2 and Corynebacterium jeikeium. J Hosp Infect. (1991) 17:35–43. 10.1016/0195-6701(91)90075-J 17. Fernández-Roblas R, Prieto S, Fernández-Roblas M, Ponte C, Soriano F. Activity of nine antimicrobial agents against Corynebacterium group D2 strains isolated from clinical specimens and skin. Antimicrob Agents Chemother. (1987) 31:821–2. 10.1128/AAC.31.5.821 18. Meria P, Desgrippes A, Arfi C, Le Duc A. En-crusted cystitis and pyelitis. J Urol. (1998) 160:3–9. 10.1097/00005392-199807000-00003 19. Nieto E, Zapardiel J, Soriano F. Environmental contamination by Corynebacterium urealyticum in a teaching hospital. J Hosp Infect. (1996) 32:78–9. 10.1016/S0195-6701(96)90172-3 20. Fosse T, Carles D, Laffont C, Lefebvre JC, Bocquet JP. Urinary Corynebacterium group D2 infections. A hospital epidemic and antibiotic sensitivity. Pathol Biol. (1988) 36:742–5. 21. Marty N, Agueda L, Lapchine L, Clave D, Henry-Ferry S, Chabanon G. Adherence and hemagglutination of Corynebacterium group D2. Eur J Clin Microbiol Infect Dis. (1991) 10:20–4. 10.1007/BF01967092 22. Soriano F, Ponte C, Galiano MJ. Adherence of Corynebacterium urealyticum (CDC group D2) and Corynebacterium jeikeium to intravascular and urinary catheters. Eur J Clin Microbiol Infect Dis. (1993) 12:453–6. 10.1007/BF01967441 23. Chung CS, Liao CH, Cheng SL, Lin TH, Hsueh PR. Percutaneous nephrostomy tube-associated bacteremia caused by Corynebacterium urealyticum. J Microbiol Immunol Infect. (2008) 41:525–7. 24. Soriano F, Huelves L, Naves P, Rodríguez-Cerrato V, del Prado G, Ruiz V, et al.. In vitro activity of ciprofloxacin, moxifloxacin, vancomycin and erythromycin against planktonic and biofilm forms of Corynebacterium urealyticum. J Antimicrob Chemother. (2009) 63:353–6. 10.1093/jac/dkn491 25. Nickel JC, Reid G, Bruce AW, Costerton JW. Ultrastructural microbiology of infected urinary stone. Urology. (1986) 28:512–5. 10.1016/0090-4295(86)90155-X 26. Garcia-Bravo M, Aguado JM, Morales JM, Noriega AR. Influence of external factors in resistance of Corynebacterium urealyticum to antimicrobial agents. Antimicrob Agents Chemother. (1996) 40:497–9. 10.1128/AAC.40.2.497 27. López-Medrano F, García-Bravo M, Morales JM, Andrés A, San Juan R, Lizasoain M, et al.. Urinary tract infection due to Corynebacterium urealyticum in kidney transplant recipients: an underdiagnosed etiology for obstructive uropathy and graft dysfunction-results of a prospective cohort study. Clin Infect Dis. (2008) 46:825–30. 10.1086/528713 28. Walkden D, Klugman KP, Vally S, Naidoo P. Urinary tract infection with Corynebacterium urealyticum in South Africa. Eur J Clin Microbiol Infect Dis. (1993) 12:18–24. 10.1007/BF01997051 29. Aguado JM, Ponte C, Soriano F. Bacteriuria with a multiply resistant species of Corynebacterium (Corynebacterium group D2): an unnoticed cause of urinary tract infection. J Infect Dis. (1987) 156:144–50. 10.1093/infdis/156.1.144 30. Zapardiel J, Nieto E, Soriano F. Evaluation of a new selective medium for the isolation of Corynebacterium urealyticum. J Med Microbiol. (1998) 47:79–83. 10.1099/00222615-47-1-79 31. Lagrou K, Verhaegen J, Janssens M, Wauters G, Verbist L. Prospective study of catalase-positive coryneform organisms in clinical specimens: identification, clinical relevance, and antibiotic susceptibility. Diagn Microbiol Infect Dis. (1998) 30:7–15. 10.1016/S0732-8893(97)00193-4 32. Ohl CA, Tribble DR. Corynebacterium group D2 infection of a complex renal cyst in a debilitated patient. Clin Infect Dis. (1992) 14:1160–1. 10.1093/clinids/14.5.1160 33. Saavedra J, Rodríguez JN, Fernández-Jurado A, Vega MD, Pascual L, Prados D. A necrotic soft-tissue lesion due to Corynebacterium urealyticum in a neutropenic child. Clin Infect Dis. (1996) 22:851–2. 10.1093/clinids/22.5.851 34. Soriano F, Ponte C, Ruiz P, Zapardiel J. Non-urinary tract infections caused by multiply antibiotic-resistant Corynebacterium urealyticum. Clin Infect Dis. (1993) 17:890–1. 10.1093/clinids/17.5.890 35. Rizvi M, Khan F, Raza A, Shukla I, Bin Sabir A. Emergence of coryneforms in osteomyelitis and orthopaedic surgical site infections. Australas Med J. (2011) 4:412–7. 10.4066/AMJ.2011.671 36. Chomarat M, Breton P, Dubost J. Osteomyelitis due to Corynebacterium group D2. Eur J Clin Microbiol Infect Dis. (1991) 10:43. 10.1007/BF01967098 37. Fernández-Natal I, Guerra J, Alcoba M, Soriano F. Bacteremia caused by multiply resistant Corynebacterium urealyticum: six case reports and review. Eur J Clin Microbiol Infect Dis. (2001) 20:514–7. 10.1007/PL00011297 38. Wood CA, Pepe R. Bacteremia in a patient with non-urinary-tract infection due to Corynebacterium urealyticum. Clin Infect Dis. (1994) 19:367–8. 10.1093/clinids/19.2.367 39. Marshall RJ, Routh KR, MacGowan AP. Corynebacterium CDC group D2 bacteraemia. J Clin Pathol. (1987) 40:813–4. 10.1136/jcp.40.7.813-c 40. Van Bosterhaut B, Claeys G, Gigi J, Wauters G. Isolation of Corynebacterium group D2 from clinical specimens. Eur J Clin Microbiol. (1987) 6:418–9. 10.1007/BF02013099 41. Williams DY, Selepak ST, Gill VJ. Identification of clinical isolates of nondiphtherial Corynebacterium species and their antibiotic susceptibility patterns. Diagn Microbiol Infect Dis. (1993) 17:23–8. 10.1016/0732-8893(93)90065-F 42. Famularo G, Minisola G, Nicotra GC, Parisi G, De Simone C. A case report and literature review of Corynebacterium urealyticum infection acquired in the hospital. Intern Emerg Med. (2008) 3:293–5. 10.1007/s11739-008-0120-8 43. Riegel P, Ruimy R, Christen R, Monteil H. Species identities and antimicrobial susceptibilities of corynebacteria isolated form various clinical sources. Eur J Clin Microbiol Infect Dis. (1996) 15:657–62. 10.1007/BF01691153 44. Jacobs NF, Jr, Perlino CA. “Diphtheroid” pneumonia. South Med J. (1979) 72:475–6. 10.1097/00007611-197904000-00026 45. Ojeda-Vargas M, Gonzalez-Fernandez MA, Romero D, Cedrés A, Monzón-Moreno C. Pericarditis caused by Corynebacterium urealyticum. Clin Microbiol Infect. (2000) 6:560–1. 10.1046/j.1469-0691.2000.00081.x 46. Ena J, Berenguer J, Peláez T, Bouza E. Endocarditis caused by Corynebacterium group D2. J Infect. (1991) 22:95–6. 10.1016/0163-4453(91)91150-V 47. Soriano F, Ponte C, Santamaría M, Castilla C, Fernández Roblas R. In vitro and in vivo study of stone formation by Corynebacterium group D2 (Corynebacterium urealyticum). J Clin Microbiol. (1986) 23:691–4. 10.1128/JCM.23.4.691-694.1986 48. Takebe S, Numata A, Kobashi K. Stone for-mation by Ureaplasma urealyticum in human urine and its prevention by urease inhibitors. J Clin Microbiol. (1984) 20:869–73. 10.1128/JCM.20.5.869-873.1984 49. Lamm DL, Johnson SA, Friedlander AM, Gittes RF. Medical therapy of experimental infection stones. Urology. (1977) 10:418–21. 10.1016/0090-4295(77)90125-X 50. Griffith DP, Musher DM, Itin C. Urease. The primary cause of infection-induced urinary stones. Invest Urol. (1976) 13:346–50. 10.1007/978-1-4613-4295-3_69 51. Daudon M, Traxer O, Jungers P. Lithiase d'infection. In: Leclerc E, Brottier B. editors. Lithiase Urinaire. 2nd ed Paris: Lavoisier; (2012). Chapter 11, p. 510–3. 52. Elliot JS, Sharp RF, Lewis L. The solubility of struvite in urine. J Urol. (1959) 81:366–8. 10.1016/S0022-5347(17)66025-7 53. Flannigan RK, Battison A, De S, Humphreys MR, Bader M, Lellig E, et al.. Evaluating factors that dictate struvite stone composition: a multi-institutional clinical experience from the EDGE Research Consortium. Can Urol Assoc J. (2018) 12:131–6. 10.5489/cuaj.4804 54. Parsons CL, Stauffer C, Mulholland SG, Griffith DP. Effect of ammonium on bacterial adherence to bladder transitional epithelium. J Urol. (1984) 132:365–6. 10.1016/S0022-5347(17)49628-5 55. Tauch A, Trost E, Tilker A, Ludewig U, Schneiker S, Goesmann A, et al.. The lifestyle of Corynebacterium urealyticum derived from its complete genome sequence established by pyrosequencing. J Biotechnol. (2008) 136:11–21. 10.1016/j.jbiotec.2008.02.009 56. Guimarães LC, Soares SC, Albersmeier A, Blom J, Jaenicke S, Azevedo V, et al.. Complete Genome Sequence of Corynebacterium urealyticum Strain DSM 7111, Isolated from a 9-Year-Old Patient with Alkaline-Encrusted Cystitis. Genome Announc. (2013) 1:e00264–13. 10.1128/genomeA.00264-13 57. Guimarães L, Soares S, Trost E, Blom J, Ramos R, Silva A, et al.. Genome informatics and vaccine targets in Corynebacterium urealyticum using two whole genomes, comparative genomics, and reverse vaccinology. BMC Genomics. (2015) 16(Suppl. 5):S7. 10.1186/1471-2164-16-S5-S7 58. Del Prete D, Polverino B, Ceol M, Vianello D, Mezzabotta F, Tiralongo E, et al.. Encrusted cystitis by Corynebacterium urealyticum: a case report with novel insights into bladder lesions. Nephrol Dial Transplant. (2008) 23:2685–7. 10.1093/ndt/gfn243 59. Yasui T, Fujita K, Asai K, Kohri K. Osteopontin regulates adhesion of calcium oxalate crystals to renal epithelial cells. Int J Urol. (2002) 9:100–8. 10.1046/j.1442-2042.2002.00429.x 60. Park JM, Faerber GJ. Corynebacterium induced urethral incrustation. J Urol. (1994) 151:1636–7. 10.1016/S0022-5347(17)35325-9 61. Meria P, Desgrippes A, Fournier R, Arfi C, Antoine C, Martinat L, et al.. The conservative management of corynebacterium group D2 encrusted pyelitis. BJU Int. (1999) 84:270–5. 10.1046/j.1464-410x.1999.00156.x 62. Giannakopoulos S, Alivizatos G, Deliveliotis C, Skolarikos A, Kastriotis J, Sofras F. Encrusted cystitis and pyelitis. Eur Urol. (2001) 39:446–8. 10.1159/000052483 63. Gross BH. Bladder and ureteral calcifications. Semin Roentgenol. (1979) 14:261–2. 10.1016/0037-198X(79)90022-1 64. Pollack HM, Banner MP, Martinez LO, et al.. Diagnostic considerations in urinary bladder wall calcification. AJR Am J Roentgenol. (1981) 136:791–2. 10.2214/ajr.136.4.791 65. Mustafa M. Erosion of an intrauterine contraceptive device through the bladder wall causing calculus: management and review of the literature. Urol Int. (2009) 82:370–1. 10.1159/000209376 66. Lenherr SM, Crosby EC, Cameron AP. Cystoscopic findings: a video tutorial. Int Urogynecol J. (2015) 26:921–3. 10.1007/s00192-014-2614-4 67. Drago PC, Badalament RA, Lucas J, Drago JR. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. J Urol. (1989) 142:1071–2. 10.1016/S0022-5347(17)38992-9 68. Walther MM, Eanes ED, Delaney TF, Travis WD. Bladder calcifications after photodynamic therapy: analysis of a rare complication. Urology. (1996) 47:831–5. 10.1016/S0090-4295(96)00047-7 69. Irwin GA, Craig R, Novotny P. CT of calcified bladder masses. Comput Radiol. (1985) 9:181–4. 10.1016/0730-4862(85)90163-5 70. Spirnak JP, Lubke WL, Thompson IM, Lopez M. Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder. Urology. (1993) 42:89–92. 10.1016/0090-4295(93)90350-J 71. Fujioka T, Ishii N, Chiba R. Pathological changes associated with topical chemotherapy of adriamycin for bladder cancer. Hinyokika Kiyo. (1983) 29:869–73. 72. Thoumas D, Darmallaicq C, Pfister C, Savoye-Collet C, Sibert L, Grise P, et al.. Imaging characteristics of alkaline-encrusted cystitis and pyelitis. AJR Am J Roentgenol. (2002) 178:389–92. 10.2214/ajr.178.2.1780389 73. Hertig A, Duvic C, Chretien Y, Jungers P, Grünfeld JP, Rieu P. Encrusted pyelitis of native kidneys. J Am Soc Nephrol. (2000) 11:1138–40. 74. Nadler RB, Hoffman TA, McClennan BL, Clayman RV. Corynebacterium urealyticum (CDC Group D2) associated with staghorn calculus: treatment by percutaneous debulking and chemolysis. J Endourol. (1996) 10:31–4. 10.1089/end.1996.10.31 75. Van Hooland S, Vandooren AK, Lerut E, Oyen R, Maes B. Alkaline encrusted pyelitis. Acta Clin Belg. (2005) 60:369–72. 10.1179/acb.2005.055 76. Van de Perre E, Reichman G, De Geyter D, Geers C, Wissing KM, Letavernier E. Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust. Front Med (Lausanne). 2021 Jan 21;7:609024. doi: 10.3389/fmed.2020.609024. PMID: 33553205; PMCID: PMC7858656. 77. Vila J, Juiz P, Salas C, Almela M, García de la Fuente C, Zboromyrska Y, et al.. Identification of clinically relevant Corynebacterium spp., Arcanobacterium haemolyticum, and Rhodococcus equi by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. (2012) 50:1745–7. 10.1128/JCM.05821-11 78. Simoons-Smit AM, Savelkoul PH, Newling DW, Vandenbroucke-Grauls CM. Chronic cystitis caused by Corynebacterium urealyticum detected by polymerase chain reaction. Eur J Clin Microbiol Infect Dis. (2000) 19:949–52. 10.1007/s100960000407 79. Domann E, Hong G, Imirzalioglu C, Turschner S, Kühle J, Watzel C, et al.. Culture-independent identification of pathogenic bacteria and polymicrobial infections in the genitourinary tract of renal transplant recipients. J Clin Microbiol. (2003) 41:5500–10. 10.1128/JCM.41.12.5500-5510.2003 80. Khamis A, Raoult D, La Scola B. rpoB gene sequencing for identification of Corynebacterium species. J Clin Microbiol. (2004) 42:3925–31. 10.1128/JCM.42.9.3925-3931.2004 81. Vaneechoutte M, Riegel P, De Briel D, Monteil H, Verschraegen G, De Rouck A, et al.. Evaluation of the applicability of amplified rDNA-restriction analysis (ARDRA) to identification of species of the genus Corynebacterium. Res Microbiol. (1995) 146:633–41. 10.1016/0923-2508(96)81061-8 82. Zheng J, Wang G, He W, Jiang N, Jiang H. Imaging characteristics of alkaline-encrusted cystitis. Urol Int. (2010) 85:364–7. 10.1159/000316552 83. Carpentier X, Daudon M, Traxer O, Jungers P, Mazouyes A, Matzen G, et al.. Relationships between carbonation rate of carbapatite and morphologic characteristics of calcium phosphate stones and etiology. Urology. (2009) 73:968–75. 10.1016/j.urology.2008.12.049 84. Soriano F, Zapardiel J, Nieto E. Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents. Antimicrob Agents Chemother. (1995) 39:208–14. 10.1128/AAC.39.1.208 85. García-Rodriguez JA, García Sánchez JE, Muñoz Bellido JL, Nebreda Mayoral T, García Sánchez E, García García I. In vitro activity of 79 antimicrobial agents against Corynebacterium group D2. Antimicrob Agents Chemother. (1991) 35:2140–3. 10.1128/AAC.35.10.2140 86. Sánchez Hernández J, Mora Peris B, Yagüe Guirao G, Gutiérrez Zufiaurre N, Muñoz Bellido JL, et al. In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum. Int J Antimicrob Agents. (2003) 22:492–6. 10.1016/S0924-8579(03)00121-3 87. Soriano F, Ponte C, Santamaría M, Fernández-Roblas R. Susceptibility of urinary isolates of Corynebacterium group D2 to fifteen antimicrobials and acetohydroxamic acid. J Antimicrob Chemother. (1987) 20:349–55. 10.1093/jac/20.3.349 88. José-Luis Gómez-Garcés JL, Alos JI, Tamayo J. In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria. Int J Antimicrob Agents. (2007) 29:688–92. 10.1016/j.ijantimicag.2006.11.032 89. Martínez-Martínez L, Pascual A, Suárez AI, Perea EJ. In vitro activity of levofloxacin, ofloxacin and D-ofloxacin against coryneform bacteria and Listeria monocytogenes. J Antimicrob Chemother. (1999) 43(Suppl C):27–32. 10.1093/jac/43.suppl_3.27 90. Martínez-Martínez L, Suárez AI, Ortega MC, Perea EJ. Comparative in vitro activities of new quinolones against coryneform bacteria. Antimicrob Agents Chemother. (1994) 38:1439–41. 10.1128/AAC.38.6.1439 91. Philippon A, Bimet F. In vitro susceptibility of Corynebacterium group D2 and Corynebacterium jeikeium to twelve antibiotics. Eur J Clin Microbiol Infect Dis. (1990) 9:892–5. 10.1007/BF01967505 92. Conejo Mdel C, Martínez-Martínez L, Pascual A, Suárez AI, Perea EJ. Activities of ABT-773 against Listeria monocytogenes and coryneform bacteria of clinical interest. Antimicrob Agents Chemother. (2003) 47:1403–6. 10.1128/AAC.47.4.1403-1406.2003 93. Bernardo NO, Smith AD. Chemolysis of urinary calculi. Urol Clin North Am. (2000) 27:355–65. 10.1016/S0094-0143(05)70264-0 94. Andersen JA. Benurestat, a urease inhibitor for the therapy of infected ureolysis. Invest Urol. (1975) 12:381–6. 95. Millner OE, Jr, Andersen JA, Appler ME, Benjamin CE, Edwards JG, Humphrey DT, et al.. Flurofamide: a potent inhibitor of bacterial urease with potential clinical utility in the treatment of infection induced urinary stones. J Urol. (1982) 127:346–50. 10.1016/S0022-5347(17)53779-9 96. Dixon NE, Gazzola C, Watters JJ, Blakely RL, Zerner B. Inhibition of Jack Bean urease (EC 3.5.1.5) by acetohydroxamic acid and by phosphoramidate. An equivalent weight for urease. J Am Chem Soc. (1975) 97:4130–1. 10.1021/ja00847a044 97. Takeuchi H, Tomoyoshi T, Okada Y, Yoshida O, Kobashi K. Prevention of infected urinary stones by urease inhibitor. IV. Treatment of infection stones in rats by a new hydroxamic acid and cefalexin. Hinyokika Kiyo. (1983) 29:297–302. 98. Munakata K, Kobashi K, Takebe S, Hase J. Therapy for urolithiasis by hydroxamic acids. III. Urease inhibitory potency and urinary excretion rate of N-acylglycinohydroxamic acids. J Pharmacobiodyn. (1980) 3:451–6. 10.1248/bpb1978.3.451 99. Ford DK. Inhibition of growth of T-strain mycoplasmas by hydroxamic acids and by aurothiomalate. Antimicrob Agents Chemother. (1972) 2:340–3. 10.1128/AAC.2.5.340 100. Hase J, Kobashi K. Inhibition of Proteus vulgaris urease by hydroxamic acids. J Biochem. (1967) 62:293–9. 101. Fishbein WN, Carbone PP. Urease catalyis. II. Inhibition of the enzyme by hydroxyurea, hydroxylamine and acetohydroxamic acid. J Biol Chem. (1965) 240:2407–14. 102. Kobashi K, Kumaki K, Hase J. Effect of acyl residues of hydroxamic acids on urease inhibtion. Biochim Biophys Acta. (1971) 227:429–41. 10.1016/0005-2744(71)90074-X 103. Fishbein WN, Daly JE. Urease inhibitors for hepatic coma. II. Comparative efficacy of four lower hydroxamate homologs in vitro and in vivo. Proc Soc Exp Biol Med. (1970) 134:1083–90. 10.3181/00379727-134-34949 104. Soriano F, Ponte C, Santamaría M, Fernández-Roblas R. Struvite crystal formation by Corynebacterium group D2 in human urine and its prevention by acetohydroxamic acid. Eur Urol. (1987) 13:271–3. 10.1159/000472793 105. Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N. Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol. (1991) 20:243–7. 10.1159/000471707 106. Williams JJ, Rodman JS, Peterson CM. A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. N Engl J Med. (1984) 311:760–4. 10.1056/NEJM198409203111203 107. Griffith DP, Khonsari F, Skurnick JH, James KE. A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J Urol. (1988) 140:318–24. 10.1016/S0022-5347(17)41592-8 108. Griffith DP, Gibson JR, Clinton CW, Musher DM. Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi. J Urol. (1978) 119:9–15. 10.1016/S0022-5347(17)57366-8 109. Bailie NC, Osborne CA, Leininger JR, Fletcher TF, Johnston SD, Ogburn PN, et al.. Teratogenic effect of acetohydroxamic acid in clinically normal beagles. Am J Vet Res. (1986) 47:2604–11. 110. Chaube S, Murphy ML. The effects of hydroxyurea and related compounds on the rat fetus. Cancer Res. (1966) 26:1448–57. 111. Martelli A, Buli P, Spatafora S. Clinical experience with low dosage of propionohydroxamic acid (PHA) in infected renal stones. Urology. (1986) 28:373–5. 10.1016/0090-4295(86)90064-6 112. Puppo P, Germinale F, Bottino P, Ricciotti G, Giuliani L. Propionhydroxamic acid in the management of struvite urinary stones. Contr Nephrol. (1987) 58:201–6. 10.1159/000414518 113. Saljoghi R, Lipsker A, Caillet K, Malaterre J, Le Roux F, Pignot G, et al.. Encrusted uretero-pyelitis: case report. Urol Case Rep. (2016) 7:58–60. 10.1016/j.eucr.2016.04.014 114. Smith MJ. Management of infected stone dis-ease with hydroxyurea: a five year follow-up. Proc Eur Dial Transplant Assoc. (1983) 20:466–8. 115. Sabiote L, Emiliani E, Kanashiro AK, Balañà J, Mosquera L, Sánchez-Martín FM, et al.. Oral acidification with L-methionine as a noninvasive treatment for encrusted uropathy. J Endourol Case Rep. (2020) 6:143–6. 10.1089/cren.2019.0164 116. Sabiote L. et al. Oral Acidification with l-Methionine as a Noninvasive Treatment for Encrusted Uropathy. Journal of Endourology case reports. 2020;6(3):143-146. DOI: 10.1089/CREN.2019.0164 117. Ozkan TA, Yalcin MS, Dillioglugil O, Cevik I. Encrusted cystitis caused by Corynebacterium urealyticum: a case report with novel treatment strategy of intravesical dimethyl sulfoxide. Int Braz J Urol. (2018) 44:1252–5. 10.1590/s1677-5538.ibju.2017.0588 118. Harrison RB, Stier FM, Cochrane JA. Alkaline encrusting cystitis. AJR Am J Roentgenol. (1978) 130:575–7. 10.2214/ajr.130.3.575 119. Domínguez-Gil B, Herrero JC, Carreño A, Morales E, Andres A, Aguado JM, et al.. Ureteral stenosis secondary to encrustation by urea-splitting Corynebacterium urealyticum in a kidney transplant patient. Nephrol Dial Transplant. (1999) 14:977–8. 10.1093/ndt/14.4.977 120. Berney DM, Thompson I, Sheaff M, Baithun SI. Alkaline encrusted cystitis associated with malakoplakia. Histopathology. (1996) 28:253–6. 10.1046/j.1365-2559.1996.d01-426.x 121. Chung SY, Davies BJ, O'Donnell WF. Mortality from grossly encrusted bilateral pyelitis, ureteritis, and cystitis by Corynebacterium group D2. Urology. (2003) 61:463. 10.1016/S0090-4295(02)02283-5 122. Audard V, Garrouste-Orgeas M, Misset B, Ben Ali A, Gattolliat O, Meria P, et al.. Fatal septic shock caused by Corynebacterium D2. Intensive Care Med. (2003) 29:1376–9. 10.1007/s00134-003-1865-1 123. Lieten S, Schelfaut D, Wissing KM, Geers C, Tielemans C. Alkaline-encrusted pyelitis and cystitis: an easily missed and life-threatening urinary infection. BMJ Case Rep. (2011) 2011:bcr1220103613. 10.1136/bcr.12.2010.3613 124. Anagnostou N, Siddins M, Gordon DL. Encrusted cystitis and pyelitis. Intern Med J. (2012) 42:596–7. 10.1111/j.1445-5994.2012.02773.x